Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 276,724
  • Shares Outstanding, K 113,878
  • Annual Sales, $ 63,530 K
  • Annual Income, $ -160,930 K
  • EBIT $ -196 M
  • EBITDA $ -181 M
  • 60-Month Beta 1.88
  • Price/Sales 4.25
  • Price/Cash Flow N/A
  • Price/Book 0.71

Options Overview Details

View History
  • Implied Volatility 258.17% ( -53.10%)
  • Historical Volatility 63.04%
  • IV Percentile 94%
  • IV Rank 71.08%
  • IV High 358.53% on 04/30/24
  • IV Low 11.45% on 09/16/24
  • Put/Call Vol Ratio 1.11
  • Today's Volume 19
  • Volume Avg (30-Day) 75
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 2,049
  • Open Int (30-Day) 1,633

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.42
  • Number of Estimates 9
  • High Estimate -0.39
  • Low Estimate -0.46
  • Prior Year -0.46
  • Growth Rate Est. (year over year) +8.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.27 +7.05%
on 10/31/24
3.35 -27.46%
on 10/04/24
-0.92 (-27.46%)
since 10/01/24
3-Month
2.27 +7.05%
on 10/31/24
4.66 -47.80%
on 08/02/24
-2.45 (-50.20%)
since 08/01/24
52-Week
1.91 +27.23%
on 11/10/23
8.83 -72.48%
on 03/07/24
+0.50 (+25.91%)
since 11/01/23

Most Recent Stories

More News
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down

Alkermes plc ALKS reported adjusted earnings from continuing operations of 73 cents per share for third-quarter 2024, which missed the Zacks Consensus Estimate of 78 cents. The company had reported adjusted...

CSTL : 33.15 (-4.38%)
ELEV : 0.5360 (-6.67%)
FATE : 2.43 (+2.53%)
ALKS : 26.47 (+3.00%)
VKTX Beats on Q3 Earnings, Stock Up on Obesity Pipeline Advancements

Viking Therapeutics VKTX reported third-quarter 2024 loss per share of 22 cents, narrower than the Zacks Consensus Estimate of a loss of 24 cents. The company had incurred a loss of 23 cents per share...

FOLD : 11.47 (+0.44%)
VKTX : 72.88 (+0.47%)
CSTL : 33.15 (-4.38%)
FATE : 2.43 (+2.53%)
Fate Therapeutics: Q2 Earnings Snapshot

Fate Therapeutics: Q2 Earnings Snapshot

FATE : 2.43 (+2.53%)
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?

The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.

MRK : 101.88 (-0.43%)
LLY : 818.93 (-1.30%)
PFE : 28.09 (-0.74%)
OPHLY : 4.2300 (+2.42%)
ABCL : 2.73 (unch)
FATE : 2.43 (+2.53%)
Fate Therapeutics: Q1 Earnings Snapshot

Fate Therapeutics: Q1 Earnings Snapshot

FATE : 2.43 (+2.53%)
5 Russell 2000 Stocks Outperforming the 'Magnificent Seven' in 2024

The "Magnificent Seven" have lost some momentum in 2024, just as small-caps are starting to come on strong. Here's a closer look at five Russell 2000 stocks that are crushing the performance of their mega-cap...

GOOGL : 171.29 (+0.11%)
AMZN : 197.93 (+6.19%)
AAPL : 222.91 (-1.33%)
META : 567.16 (-0.07%)
MSFT : 410.37 (+0.99%)
NVDA : 135.40 (+1.99%)
TSLA : 248.98 (-0.35%)
MAGS : 48.02 (+1.18%)
$IUXX : 20,033.14 (+0.72%)
VKTX : 72.88 (+0.47%)
SOUN : 5.14 (+2.19%)
APGE : 54.49 (+4.71%)
Fate Therapeutics: Q4 Earnings Snapshot

Fate Therapeutics: Q4 Earnings Snapshot

FATE : 2.43 (+2.53%)
Fate Therapeutics: Q3 Earnings Snapshot

Fate Therapeutics: Q3 Earnings Snapshot

FATE : 2.43 (+2.53%)
Fate Therapeutics: Q2 Earnings Snapshot

Fate Therapeutics: Q2 Earnings Snapshot

FATE : 2.43 (+2.53%)
Why Shares of Fate Therapeutics Soared This Week

The company's shares bounced back after a stock sale last week.

JNJ : 160.13 (+0.17%)
OPHLY : 4.2300 (+2.42%)
FATE : 2.43 (+2.53%)
MFG : 4.31 (+1.89%)

Business Summary

Fate Therapeutics is a clinical-stage biopharmaceutical company, which is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.' The company uses various therapeutic approaches for cell programming to develop cell therapies. The company programs cells of the...

See More

Key Turning Points

3rd Resistance Point 2.66
2nd Resistance Point 2.57
1st Resistance Point 2.50
Last Price 2.43
1st Support Level 2.34
2nd Support Level 2.25
3rd Support Level 2.18

See More

52-Week High 8.83
Fibonacci 61.8% 6.19
Fibonacci 50% 5.37
Fibonacci 38.2% 4.55
Last Price 2.43
52-Week Low 1.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar